Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Unknown 3Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1

Interventions

Cyclophosphamide 10Rituximab 9polatuzumab vedotin 6Prednisone 6Doxorubicin 6Vincristine 5zanubrutinib 4glofitamab 4Prednisolone 4Lenalidomide 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Lisaftoclax 3tafasitamab 2obinutuzumab 2fludarabine 2Radiotherapy 2R-CHOP protocol 2Observation 2venetoclax 1sintilimab 1resiniferatoxin 1penpulimab 1pegfilgrastim 1orelabrutinib 1loncastuximab tesirine 1duvelisib 1acalabrutinib 1Vancomycin 1Therapeutics 1Tamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Lymphoma, Large B-Cell, Diffuse × orelabrutinib × Clear all
NCT06516978 2024-07-24

A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
528 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡